NCT04083599 2026-03-16GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid TumorsGenmabPhase 1/2 Active not recruiting350 enrolled
NCT06607185 2026-03-13A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid TumorsEli Lilly and CompanyPhase 1 Active not recruiting750 enrolled
NCT06385925 2025-12-15A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D MutationTyligand Pharmaceuticals (Suzhou) LimitedPhase 1/2 Recruiting440 enrolled
NCT07259590 2025-12-02A Study of GFH375 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors Harboring KRAS G12D MutationGenfleet Therapeutics (Shanghai) Inc.Phase 1/2 Recruiting126 enrolled
NCT03169777 2025-02-21QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRCImmunityBio, Inc.Phase 1/2 Withdrawn
NCT03678883 2024-11-079-ING-41 in Patients with Advanced CancersActuate Therapeutics Inc.Phase 2 Active not recruiting350 enrolled